via Brigham and Women’s Hospital
Scientists at Brigham and Women’s Hospital (BWH) have developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The work is a major biomedical advancement that will help address blood transfusion needs worldwide.
The study is published July 21, 2014 in Blood.
“The ability to generate an alternative source of functional human platelets with virtually no disease transmission represents a paradigm shift in how we collect platelets that may allow us meet the growing need for blood transfusions,” said Jonathan Thon, PhD, Division of Hematology, BWH Department of Medicine, lead study author.
According to the researchers, more than 2.17 million platelet units from donors are transfused yearly in the United States to treat patients undergoing chemotherapy, organ transplantation and surgery, as well as for those needing blood transfusions following a major trauma. However, increasing demand; a limited five-day shelf-life; and risk of contamination, rejection and infection have made blood platelet shortages common.
“Bioreactor-derived platelets theoretically have several advantages over conventional, donor-derived platelets in terms of safety and resource utilization,” said William Savage, MD, PhD, medical director, Kraft Family Blood Donor Center at Dana Farber Cancer Institute/Brigham and Women’s Hospital, who did not contribute to the study. “A major factor that has limited our ability to compare bioreactor platelets to donor platelets is the inefficiency of growing platelets, a problem that slows progress of clinical research. This study addresses that gap, while contributing to our understanding of platelet biology at the same time.”
Read more . . .
The Latest on: Platelet bioreactor
via Google News
The Latest on: Platelet bioreactor
- Molecular medicine reportson July 28, 2022 at 5:00 pm
Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Downregulation of the ...
- Pediatric Genetic Disease Treatment Market Size, Share, Emerging Trends, Historic Analysis and Industry Growth Factors by 2028on July 26, 2022 at 7:21 am
The MarketWatch News Department was not involved in the creation of this content. Jul 26, 2022 (Heraldkeepers) -- Pediatric Genetic Disease Treatment Market survey report recognizes and analyses ...
- Transplantation of Engineered Heart Tissue as a Biological Cardiac Assist Device for Treatment of Dilated Cardiomyopathyon July 21, 2022 at 5:00 pm
The present idea is to pre-seed a decellularized artery with autologous endothelial progenitor cells for some days of culture in a rotating bioreactor. Thereafter, this pre-cultivated vessel ...
- Bulls remain hopeful LaVine will choose to remain in Chicagoon June 27, 2022 at 12:05 pm
LaVine had platelet-rich plasma therapy, a cortisone injection and fluid drained from his knee in Los Angeles before the All-Star break. He had arthroscopic surgery on it last month. Story continues ...
- Stem Cells in the Treatment of Diseaseon May 2, 2019 at 12:38 am
A hurdle for both red cells and platelets is that generation from PSCs remains inefficient and costly. Advances are needed to achieve commercial viability, including refinement of bioreactors and ...
- Modern microbial seascapeson October 1, 2007 at 5:00 am
Collectively, the sub-seafloor can be viewed as an enormous microbial 'bioreactor', that processes ... which they biomineralize different calcitic platelets (coccoliths) to cover their cells.
via Bing News
